Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L B van de Putte

Showing results (11-20 of 372) with videos related to

Pageof 38
Sort By:
Clinical and Experimental Rheumatology|May 1, 1997
Currently used second-line agents: do they control the disease course?L B van de Putte, P L van Riel
Nederlands Tijdschrift Voor Geneeskunde|April 8, 1989
[Slow-acting antirheumatic agents]L B van de Putte, P L van Riel
Agents and Actions. Supplements|January 1, 1979
Proliferative lesion of arthritis: a target for therapy?L B Van De Putte, H J Van Beusekom
The Netherlands Journal of Medicine|June 1, 1990
Sulphasalazine in the treatment of rheumatoid arthritis: a renewed challengeP L van Riel, L B van de Putte
The Journal of Rheumatology. Supplement|September 1, 1994
DC-ART: what proportion of response constitutes a positive response?P L van Riel, L B van de Putte
Zeitschrift Fur Rheumatologie|December 29, 1998
[Therapy of refractory chronic polyarthritis with tumor necrosis factor alpha receptor fusion proteins (TNFR55-IgG1)--results of double-blind placebo-controlled studies over 3 months]L B van de Putte, O Sander, R Rau
Clinical and Experimental Rheumatology|September 1, 1995
Rheumatoid arthritis: new trends in therapyL B van de Putte, P L van Riel
Current Opinion in Rheumatology|March 1, 1994
Clinical assessment and clinical trials in rheumatoid arthritisP L van Riel, L B van de Putte
Acta Orthopaedica Scandinavica. Supplementum|October 1, 1995
Rheumatoid arthritis--changing theories and treatment modalitiesL B van de Putte, P L van Riel
Physiology & Behavior|April 1, 1996
Predominant right leg dysfunction without asymmetric muscle inflammation in CD1 Swiss mice with coxsackievirus B1-induced myositisP J Jongen, P Eling, L B Van de Putte
Pageof 38

Showing results (11-20 of 372) with videos related to

Sort By:
Pageof 38
Clinical and Experimental Rheumatology|May 1, 1997
Currently used second-line agents: do they control the disease course?L B van de Putte, P L van Riel
Nederlands Tijdschrift Voor Geneeskunde|April 8, 1989
[Slow-acting antirheumatic agents]L B van de Putte, P L van Riel
Agents and Actions. Supplements|January 1, 1979
Proliferative lesion of arthritis: a target for therapy?L B Van De Putte, H J Van Beusekom
The Netherlands Journal of Medicine|June 1, 1990
Sulphasalazine in the treatment of rheumatoid arthritis: a renewed challengeP L van Riel, L B van de Putte
The Journal of Rheumatology. Supplement|September 1, 1994
DC-ART: what proportion of response constitutes a positive response?P L van Riel, L B van de Putte
Zeitschrift Fur Rheumatologie|December 29, 1998
[Therapy of refractory chronic polyarthritis with tumor necrosis factor alpha receptor fusion proteins (TNFR55-IgG1)--results of double-blind placebo-controlled studies over 3 months]L B van de Putte, O Sander, R Rau
Clinical and Experimental Rheumatology|September 1, 1995
Rheumatoid arthritis: new trends in therapyL B van de Putte, P L van Riel
Current Opinion in Rheumatology|March 1, 1994
Clinical assessment and clinical trials in rheumatoid arthritisP L van Riel, L B van de Putte
Acta Orthopaedica Scandinavica. Supplementum|October 1, 1995
Rheumatoid arthritis--changing theories and treatment modalitiesL B van de Putte, P L van Riel
Physiology & Behavior|April 1, 1996
Predominant right leg dysfunction without asymmetric muscle inflammation in CD1 Swiss mice with coxsackievirus B1-induced myositisP J Jongen, P Eling, L B Van de Putte
Pageof 38